Pharma BD Deal Intelligence
Roche snags another Alzheimer antibody from AC Immune in $418M plus deal for semorinemab anti-tau therapeutic candidate
Roche ducks out of AC Immune Alzheimer antibody alliance returning rights to two programs after nearly two decades of collaboration
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
In June 2012, AC Immune entered its second exclusive worldwide license and research collaboration with Genentech (a member of the Roche Group), covering AC Immune's anti-tau antibody program — the asset that became semorinemab. AC Immune received an undisclosed upfront payment (~CHF 59M / $68M) and was eligible for milestones exceeding CHF 400 million (~$418M) across Alzheimer's disease and other indications, plus tiered royalties. The pact extended a relationship begun with the companies' 2006 anti-amyloid-beta collaboration on crenezumab. Roche/Genentech returned global rights to both crenezumab and semorinemab to AC Immune in 2024, ending the ~18-year alliance after the antibodies failed to demonstrate sufficient clinical benefit.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / AC Immune SA (this deal) | 2012 | $718M | 41 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2012 deals · Roche Holding AG deals · Neurology deals